Polyamine Analogue PG11047
A second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth. [ ]
Term info
Polyamine Analogue PG11047
- BESpm
- CGC-11047
- N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine
- N(1),-N(12)-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride
- N(1),N(12)-bisethylspermine
- PG11047
- Polyamine Analogue PG11047
- SL-11047
- SL11047
NCIT_C128784, NCIT_C157711, NCIT_C157712
A substance that is being studied in the treatment of lymphoma. It belongs to the family of drugs called polyamine analogs.
SL11047
467739
467739
Polyamine Analogue PG11047
Pharmacologic Substance, Organic Chemical
C1963112
C60816